AI in GI endoscopy has moved from “cool demos” to clinically tested tools, with the strongest evidence in colonoscopy. Across multiple randomized trials and meta-analyses, computer-aided detection (CADe) consistently boosts polyp/adenoma detection (about a ~20% lift on average), while newer systems are reducing the false-alert problem that can drive “alert fatigue.” Computer-aided diagnosis (CADx) is improving real-time polyp characterization, but still needs stronger prospective data before “resect-and-discard” becomes routine. Beyond detection, quality-control AI (cecal intubation confirmation, bowel prep scoring, withdrawal optimization) is emerging as the next leap—shifting toward full “AI-guided endoscopy platforms.” Upper GI, EUS/ERCP, capsule, and IBD surveillance applications…
Author: Abhay Panchal
The FDA has taken a landmark step in drug development by qualifying its first artificial intelligence tool, AIM-MASH AI Assist, to help score liver biopsies in metabolic dysfunction–associated steatohepatitis (MASH) clinical trials. Developed by PathAI, the system uses machine learning to standardize notoriously variable histologic assessments while keeping pathologists firmly in the loop. Experts say the move could cut noise, speed trials, and accelerate much-needed therapies for a growing global liver disease crisis—signaling how AI is beginning to reshape how new drugs reach patients.
Dr. David Lieberman’s career helped define how modern gastroenterology thinks about colorectal cancer screening, quality, and follow-up. From shaping national colonoscopy quality benchmarks and unified screening guidelines to building foundational biorepositories and databases, his work reframed screening as a system — not just a test. Now, as blood-based screening and risk-stratified approaches emerge, Lieberman’s focus has shifted to the biggest unresolved gap: ensuring patients who start screening actually complete it — because participation, not technology alone, ultimately determines whether screening saves lives.
Gastroenterology practices in the U.S. are operating under mounting pressure in 2025. According to Medscape’s Gastroenterology Practice Issues Report, GI physicians are navigating a difficult landscape marked by specialist shortages, clinician burnout, increasing administrative burden, and early—but meaningful—impacts of artificial intelligence (AI) on daily practice. A nationwide shortage of gastroenterologists has made it harder for practices to fill open physician roles, while patient demand continues to rise. At the same time, administrative responsibilities have intensified, contributing to fatigue and reduced capacity. Medscape’s survey highlights that these combined factors are reshaping how GI practices function and scale.
As mailed stool-based colorectal cancer screening expands, the AGA is scrutinizing how insurers target patients, guide those with unclear risk, and ensure timely follow-up colonoscopies after positive results. The association is actively engaging payors to close gaps and is asking members to share de-identified patient instruction letters to improve program quality and continuity of care.
Natera has acquired liquid biopsy startup Foresight Diagnostics in a deal valued at up to $450 million, strengthening its push into ultra-sensitive molecular residual disease (MRD) detection, particularly in lymphoma. The all-stock transaction includes $275 million upfront and up to $175 million tied to future revenue and reimbursement milestones. The acquisition brings Foresight’s PhasED-Seq technology into Natera’s Signatera platform. Unlike conventional liquid biopsy approaches, PhasED-Seq requires detection of multiple mutations on the same DNA molecule, a design intended to sharply reduce sequencing errors and enable detection of circulating tumor DNA at extremely low levels. Foresight claims the method is up…
Penn State College of Medicine has received a $4.2 million, five-year grant from the CDC to expand colorectal cancer screening across rural and underserved communities in Pennsylvania, marking the first time the state has been awarded CDC funding specifically for colorectal cancer screening efforts. The initiative will launch PA-CARES, a statewide alliance designed to raise screening rates in 28 counties with the lowest participation, many of which are considered “screening deserts” due to barriers such as cost, transportation, limited provider access, and weak follow-up pathways. The program focuses not only on increasing screening uptake but also on system-level change, embedding…
Several important motility coding changes are set to take effect January 1, 2026, reshaping how key neurogastroenterology procedures are billed across outpatient settings. Most notably, EndoFLIP™ will now be billable in the ambulatory surgery center (ASC) after years of advocacy from GI societies—opening the door to broader procedural flexibility. At the same time, long-standing CPT codes for anorectal manometry and barostat are being retired, replaced with new, clearly separated Category I codes intended to eliminate historical billing confusion and duplicate reporting. The update also introduces a new permanent CPT code for IB-Stim®, transitioning the therapy out of temporary “new technology”…
The AGA released a living guideline for moderate-to-severe Crohn’s disease (published in Gastroenterology, Dec 2025) that pushes clinicians toward earlier use of high-efficacy “advanced” therapies (biologics/small molecules) rather than waiting through insurance-driven step therapy. Key takeaways:
The Centers for Medicare and Medicaid Services (CMS) has released the final 2025 Merit-based Incentive Payment System (MIPS) eligibility determinations, updated with Medicare Part B claims and Medicare Provider Enrollment, Chain, and Ownership System (PECOS) data through Sept. 30, 2025. All clinicians are encouraged to verify their status using the QPP Participation Status Tool, as eligibility may have changed, particularly for those who joined a new practice within the past year. Updates to rural special status are also expected by the end of December.